Screener
Agios Pharmaceuticals AGIO Balance Sheet Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $99.65M+23.2% | $113.6M+43.9% | $89.13M+16.9% | $92.71M-63.5% | $80.87M-4.3% | ||
| $517.93M-39.6% | $623.44M-23.4% | $765.3M-6.4% | $860.15M+14.5% | $858.07M+76.8% | ||
| $24.22M+386% | $16.13M+382% | $10.58M+157% | $5.03M+61.3% | $4.99M+32.5% | ||
| $5.6M-81.8% | $35.09M+18.5% | $0-100% | $32.03M+21.2% | $30.85M+28.9% | ||
| $717.67M-29.6% | $834.84M-13.8% | $942.05M-2.4% | $1.03B-3.8% | $1.02B+61.3% | ||
| $9.95M-6.0% | $10.57M-4.5% | $10.78M-7.7% | $10.68M-9.7% | $10.58M-16.9% | ||
| $1.11B-24.7% | $1.18B-23.8% | $1.3B-22.0% | $1.39B-22.7% | $1.47B+90.3% | ||
| $16.35M-6.8% | $13.75M+0.2% | $18.36M+10.3% | $19.55M+14.1% | $17.53M+74.7% | ||
| $70.22M-0.3% | $58.85M+12.4% | $82.21M+1.3% | $74.76M-37.4% | $70.41M+12.4% | ||
| $82.4M-19.0% | $75.88M-14.7% | $104.11M-14.8% | $101.38M-38.6% | $101.68M-9.7% | ||
| $76K+2.7% | $76K+2.7% | $75K+2.7% | $74K+1.4% | $74K+1.4% | ||
| -$761.52M-117% | -$660.82M-177% | -$561.71M-277% | -$453.67M-766% | -$350.23M+65.0% | ||
| $1.03B-25.1% | $1.11B-24.4% | $1.19B-22.6% | $1.28B-21.0% | $1.37B+107% | ||
| $1.11B-24.7% | $1.18B-23.8% | $1.3B-22.0% | $1.39B-22.7% | $1.47B+90.3% |
FAQ
- What are Agios Pharmaceuticals's total assets?
- Agios Pharmaceuticals (AGIO) holds $1.1B in total assets, down 24.7% year over year.
- How much debt does Agios Pharmaceuticals have?
- Agios Pharmaceuticals carries $31.2M in total debt against $1.0B of shareholders' equity, a debt-to-equity ratio of 0.03.
- How much cash does Agios Pharmaceuticals have?
- Agios Pharmaceuticals holds $99.6M in cash and equivalents.
- Can Agios Pharmaceuticals cover its short-term obligations?
- Its current ratio is 10.22 — current assets exceed current liabilities.
- Where does Agios Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Agios Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
